Thomas Cavanagh - Chief Executive Officer

Thomas Cavanagh

Chief Executive Officer

Thomas is a co-founder, the Chief Executive Officer and a Board member at Oxular Limited. Thomas is an experienced ophthalmic pharmaceutical industry executive with significant product development and transaction experience. He was formerly co-founder and Chief Executive Officer of Aciex Therapeutics, where he brought its lead program to NDA, oversaw the development of a novel API technology which became the basis for future products and led a successful M&A exit. His prior professional history includes positions as both a company officer and a consultant where he worked in operational and advisory roles related to capital raises, M&A transactions, industry consolidations, strategic planning, debt financings and post-merger integration. Thomas has an MBA from the Kellogg School of Management and a BSc from Binghamton University.

Ronald Yamamoto - Chief Scientific Officer

Ronald Yamamoto

Chief Scientific Officer

Ronald is a co-founder, the Chief Scientific Officer and a Board member at Oxular Limited. Ronald has more than 30 years of medical device and drug product development experience. He has led multi-disciplinary technical teams, clinical trial development and product registration in the US, the EU, China and Brazil. His ophthalmic experience includes development of novel microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal access devices, diagnostic microspheres and drug-releasing implants. Ronald’s technical background is in chemical engineering, biomaterials engineering and biochemistry and he is the inventor on more than 40 granted patents related to medical products. Ronald has a BSc in Chemical Engineering from the California Institute of Technology, an MSc in Biomaterials Engineering from Clemson University and has completed additional postgraduate studies in Biochemistry at Clemson University and the University of Southern California.

Marc de Smet - Chief Medical Officer

Marc de Smet

Chief Medical Officer
Marc is the Chief Medical Officer of Oxular Limited and a practicing vitreoretinal surgeon. Marc has over 30 years of experience in ophthalmic drug and medical device development. Previously, Marc was the NEI/NIH representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He also initiated the use of Methotrexate for the treatment of intraocular lymphoma and intraocular tuberculosis. In collaboration with Thrombogenics, Marc was responsible for preclinical and clinical activities of Ocriplasmin, leading to the commercialization of Jetrea. Marc participated in the launch OTI’s transversal retinal OCT imaging and the development of Preceyes BV’s tele-operated robot dedicated to eye surgery. Marc holds a BSC (hon) from the University of Ottawa, MD from McGill University, and a PhD from the University of Amsterdam. Marc completed residency in Ophthalmology in UBC, Vancouver, a fellowship in Uveitis at the NEI, and a VR fellowship at Johns Hopkins. Marc also held posts a head of the clinical immunology department of the NEI/LI and department head of Ophthalmology at the University of Amsterdam.
Stacey Tucker - Finance Director

Stacey Tucker

Finance Director

Stacey oversees Oxular’s finance and administration functions, providing objectivity and leadership as the Company’s chief fiduciary. Stacey has significant experience across the entire finance function including cash flow management and operational forecasting, accounting and reporting, tax reporting, financial audits, and R&D tax credits filings, general business transactions, human resources and oversight of general administration. Stacey has significant experience in supporting business financings and investor and board relations. Stacey also coordinates information technology and accounting systems, insurance programs, and technology grant applications. Stacey holds a BA (hons) in Accounting and Taxation from Bournemouth University and is also an ACCA qualified accountant. Stacey previously led finance teams in several industries including publishing and aviation.  In 2010, she lead Hangar8’s public listing in 2010 and reverse takeover with Gama Aviation in 2015. Stacey holds a BA (hons) in Accounting and Taxation from Bournemouth University and is also an ACCA qualified accountant.

Scroll to Top